|
Drug utilization mg/day | Baseline | 12 months | 24 months | 36 months |
|
ACE inhibitors | 54 patients | 89 patients | 94 patients | 164 patients |
Enalapril, mean (±SD) dose | 27. 4 ± 4.3 | 25.56 ± 3.65 | 25.56 ± 3.65 | 25.56 ± 3.65 |
Ramipril, mean (±SD) dose | 3.41 ± 2.8 | 3.1 ± 1.89 | 3.1 ± 1.89 | 3.1 ± 1.89 |
Quinapril, mean (±SD) dose | 5.11 ± 1.1 | 7.41 ± 0.8 | 7.6 ± 1.4 | 9.41 ± 1.8 |
|
Sartan | 78 patients | 67 patients | 89 patients | 102 patients |
Losartan, mean (±SD) dose, | 45.56 ± 23.54 | 49.67 ± 21.23 | 49.67 ± 21.23 | 49.67 ± 21.23 |
Telmisartan, mean (±SD) dose | 43.12 ± 12.23 | 45.12 ± 1.45 | 40.2 ± 9.7 | 41.3 ± 9.6 |
Candesartan, mean (±SD) dose | 16. 2 ± 2.32 | 16. 7 ± 6.16 | 12. 2 ± 5.65 | 14. 2 ± 4.32 |
|
Calcium antagonists | 84 patients | 93 patients | 123 patients | 153 patients |
Amlodipine, mean (±SD) dose | 6.0 ± 4.10 | 5.6 ± 2.34 | 5.6 ± 2.34 | 5.6 ± 2.34 |
Felodipine, mean (±SD) dose | 7.5 ± 2.21 | 6.9 ± 3.5 | 6.9 ± 3.5 | 6.9 ± 3.5 |
Lacidipine, means (±SD) dose | 4.5 ± 1.34 | 7.5 ± 0.21 | 7.67 ±1.3 | 5.56 ± 2.7 |
|
Antidiabetic medication | 86 patients | 112 patients | 98 patients | 105 patients |
Glimepiride, mean (±SD) dose | 1.0 ± 0.34 | 1.5 ± 0.56 | 1.43 ± 0.87 | 2.5 ± 0.12 |
Glibenclamide, mean (±SD) dose | 5.5 ± 2.12 | 6.7 ± 1.43 | 7.5 ± 2.12 | 7.7 ± 3.5 |
Repaglinide, mean (±SD) dose | 2.5 ± 0.34 | 2.65 ± 1.34 | 3.0 ± 1.31 | 4.0 ± 0.3 |
Metformina, mean (±SD) dose | 950.5 ± 43.30 | 1200.5 ± 140.3 | 950.7 ± 443.3 | 1150.5 ± 153.3 |
|
Antiplatelet drugs | 111 patients | 149 patients | 210 patients | 249 patients |
Ticlopidine, mean (±SD) dose | 250 mg, b.i.d | 250 mg b.i.d | 250 mg b.i.d | 250 mg b.i.d |
|
ASA | 117 patients | 224 patients | 326 patients | 378 patients |
Mean (±SD) dose | 300 | 300 | 300 | 300 |
|
Digoxin | 23 patients | 25 patients | 25 patients | 25 patients |
Mean (±SD) dose | 0.23 ± 0.12 | 0.22 ± 0.13 | 0.22 ± 0.13 | 0.22 ± 0.13 |
|
Loop diuretics | 53 patients | 87 patients | 78 patients | 96 patients |
Furosemide | 29.45 ± 7.89 | 28.56 ± 8.92 | 28.56 ± 8.92 | 28.56 ± 8.92 |
|
Thiazide diuretics | 65 patients | 87 patients | 93 patients | 114 patients |
Amiloride or hydrocnlorothiazide, mean (±SD) | 14.7 ± 7.50 | 17.7 ± 3.50 | 17.7 ± 3.50 | 17.7 ± 3.50 |
|
Lipid lowering drugs | 87 patients | 124 patients | 84 patients | 84 patients |
Torvastatin mean (±SD) dose | 20.34 ± 8.76 | 21.34 ± 6.76 | 21.34 ± 6.76 | 21.34 ± 6.76 |
Simvastatin mean (±SD) dose | 21.34 ± 7.67 | 22.43 ± 7.21 | 22.43 ± 7.21 | 22.43 ± 7.21 |
Pravastatin mean (±SD) dose | 19.87 ± 8.67 | 24.54 ± 8.12 | 24.54 ± 8.12 | 24.54 ± 8.12 |
|
Nitroglycerine or analogue | 126 patients | 119 patients | 139 patients | 149 patients |
Isosorbide mononitrate, mean (±SD) dose | 36.67 ± 11.2 | 35.34 ± 10.56 | 35.34 ± 10.56 | 35.34 ± 10.56 |
|
Bronchodilators | 59 patients | 87 patients | 97 patients | 104 patients |
Steroids, mean (±SD) dose | 25.78± 11.2 | 31.8± 7.7 | 21.8± 6.5 | 31.8± 7.3 |
|
A combination of the above therapies | 112 patients | 183 patients | 245 patients | 345 patients |
|